CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal

MER511Positive
AI Analysis

Summary

Eli Lilly acquired Merida in a $2.9 billion deal to expand its pipeline with MER511, a Phase 1 program for Graves' disease and thyroid eye disease.

Clinical Trial Data

Phase

Phase 1

Importance:7/10
Sentiment:
0.60
M&AacquisitionPhase 1Graves' diseasethyroid eye disease
Related Companies

Read the original article

Published by Pharmaceutical Technology on September 1, 2026 10:15 AM

Read Original